股票代码：******
网站地图
Oct 06,2014
Chinese Medicine: The Patent Dilemma Under the "Generic" System
As the third year after joining the "WTO" organization, some have called this year the beginning of the "post-WTO transition period." After experiencing the adjustment period of the first two years, deep-seated issues in China's integration with the international community have gradually emerged, among which intellectual property has increasingly become an unavoidable focal issue. This year, the dispute between multinational pharmaceutical giant Pfizer and more than ten domestic pharmaceutical companies over Viagra is seen by industry insiders as a landmark event revealing the long-standing intellectual property bottleneck troubling China's pharmaceutical industry; in fact, it is an intellectual property battle. It is understood that Pfizer underwent a 10-year research process to invent Viagra.
Oct 06,2014
International medical personnel remind disaster area residents to beware of tetanus
Xinhua Net Jakarta, January 15 (Reporters Wu Qiang, Yu Qianliang) The international medical relief organization "Doctors Without Borders" reminded residents in the Aceh disaster area of Indonesia on the 15th to be cautious of tetanus infection when clearing debris. Currently, the Aceh disaster area is hot and rainy, and many decomposing corpses are still buried in the rubble. People searching for useful items in the ruins of destroyed houses are easily infected with tetanus bacteria. Officials from "Doctors Without Borders" said the organization has found 67 cases of tetanus in the city of Banda Aceh, and it is estimated that the number of tetanus infections will significantly increase in the coming days. These officials warned that even with immediate treatment, infection
Oct 06,2014
China is a major global producer of raw pharmaceutical materials and an even larger consumer of medicines. However, the chemical drugs produced domestically currently lack independent intellectual property rights, with 97% being generic drugs, placing China at a disadvantage in international competition. In response, relevant experts have proposed suggestions for the future R&D direction and product structure adjustment of Chinese pharmaceutical companies. Adjusting the product structure to implement more "three-dimensional cross" approaches. Nowadays, people increasingly value health and improving quality of life. Coupled with the accelerated construction of the public health system, the improvement of disease prevention and control systems, the strengthening of rural medical and health infrastructure, and the establishment of new cooperative medical systems, this has created favorable conditions for the pharmaceutical economy.
Oct 06,2014
Hypertension vaccine expected to be available within five years
In the near future, some hypertension patients may be able to effectively control their blood pressure simply by receiving a vaccine injection. This therapeutic vaccine is the result of years of research by a Swiss pharmaceutical company. Currently, the vaccine is still in small-scale clinical trials, with 48 hypertension patients having completed one injection course. The expected blood pressure-lowering effect can last for about 4 months. It is reported that the vaccine will be marketed within five years, and the related research results have been published in the renowned British medical journal The Lancet. The hypertension vaccine mainly targets the renin-angiotensin system; once injected into the body, the vaccine "infects" the patient and stimulates the immune system
Oct 06,2014
Zhejiang established the nation's first non-profit joint drug procurement center
On August 18, more than 50 pharmacy owners from 11 cities in Zhejiang Province gathered in Hangzhou to officially establish the "Zhejiang Province Pharmaceutical Retail (Chain) Enterprise Joint Procurement Center." They decided to collectively conduct drug bidding with pharmaceutical manufacturers to reduce costs and seek new development opportunities. This is the first non-profit joint drug procurement center in Zhejiang Province and even nationwide. Industry insiders say this marks a shift in the pharmacy industry from passive price reductions to "active initiatives." The development of pharmacies has reached a freezing point. One of the initiators of this joint procurement center, Lin Zhenhua, General Manager of Hangzhou Buyi Pharmacy, told reporters that since 2002
Add:
Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, P.R.China.
Telephone:
Email:
Pharmacovigilance collection mailbox:
Pharmacovigilance telephone:
Microofficial website
0796-8403905
E-mail 